The Operating Theatre Journal - Journal - Page 38
Lifespin Announces the Launch
of its First Commercial Product in
Regulated Healthcare
Lifespin™ Amino Acid Profiler - A
Comprehensive Amino Acid Panel
Based on Lifespin’s AI-Driven
Metabolic Profiling Platform
Lifespin GmbH, a start-up medical
diagnostics company with offices
in Regensburg (Germany) and
Boston (MA), announced on the
22nd May that it has launched
Lifespin™ Amino Acid Profiler
(LAAP) - its first commercial
product for use in the regulated
diagnostics field. Utilizing its
proprietary AI-driven technology,
Lifespin LAAP analyzes variations
in patients’ metabolism to provide
clinicians with deep insights into
patients’ health and wellbeing.
“Lifespin LAAP will be a new
and powerful tool for physicians
to better assess and benchmark
the overall systemic wellbeing of
their patients across a wide range
of important metabolic health
markers,”
said Dr. Ali Tinazli, CEO of
Lifespin.
“We are excited to enter the
commercial stage, which will
support our mission to advance
the science of using digital
metabolic profiles for the early
detection of health conditions,
stages of diseases, and monitoring
treatment success.”
“Identifying
and
analyzing
variations
in
the
human
metabolome as a cost-effective
and highly scalable precision
diagnostics tool has long been
of great interest to medical
researchers,”
said Dr. Roland Geyer, Lifespin’s
Chief Operating Officer.
“Establishing a quantitative link
in these variations to the presence
of various disease states, prior to
the onset of symptoms, would
open the door to a far more
precise, and disruptive form of
diagnostics.
Dr Ali Tinazli CEO Lifespin
Amino acids have been shown
to play a fundamental role in
maintaining and controlling the
normal physiological processes
of the human body. From a 0.5
mL venous blood sample, LAAP
quantitatively first captures a
digital snapshot of 26 important
amino acids and then uses
proprietary algorithms to compare
an individual patient’s levels
against Lifespin’s deep database
of more than 200,000 patient
samples. In combination with
established clinical standards, the
resulting LAAP profile provides
healthcare professionals with
powerful analysis of key amino
acids derivatives to deliver
precise insights into a patient’s
health status on a number of
critical fronts. These range from
monitoring the nutrition and
health status of elderly patients
to the chronically ill.
38
This new diagnostics method
could eventually become the
gold standard for numerous
indications and new diagnostic
products where none exist
today, including in precision
drug monitoring for clinical,
pharmaceutical and research
settings; and precision nutrition
for diabetes, obesity, dietary and
lifestyle interventions.”
Lifespin’s
comprehensive
quantitative amino acid panel will
initially be made available directly
to healthcare providers in Europe,
followed by global markets in
the United States and selected
countries in Asia-Pacific as a
laboratory developed test, which
is a type of in vitro diagnostic test
that is designed, developed, and
used within a single laboratory.
Analysis of the samples will
be implemented by Lifespin at
its sites in Germany and the
US, utilizing its advanced and
proprietary testing algorithms,
and delivered to laboratory
chain companies and healthcare
providers as a Software-as-aService (SaaS).
SOURCE Lifespin
https://lifespin.health
When responding please quote ‘OTJ’
Bio-Gate and OSSIS expand into additional
international markets with HyProtect™
Coatings on Compassionate Care implants.
• Stronger and expanded international market access of
OSSIS after acquisition by Zimmer Biomet
• Increased awareness of HyProtect™ coatings
• Increased volume of HyProtect™ coated implants
Bio-Gate AG, a leading provider of innovative technologies and
individual solutions for health and hygiene, will introduce and market
the innovative HyProtect™ coating technology into additional markets
in the future via its long-term partner OSSIS Ltd. from New Zealand.
The cooperation primarily relates to single patient compassionate care
cases in human medicine with orthopedic revision implants.
Bio-Gate has already been successfully working together with OSSIS
for several years, coating revision implants with the HyProtect™
technology. Bio-Gate coats titanium implants that are manufactured by
Ossis using 3D printing and which are predominantly used in orthopedic
revisions for patients who are particularly at risk of infection.
Our cooperation partner recently accepted an acquisition offer from
Zimmer Biomet – a global medical device technology manufacturer.
The cooperation with Bio-Gate will continue unchanged and, due to
the high quality of the HyProtect™ coating in the compassionate care
sector, will now even be extended to further regions worldwide via the
expanded global network.
Bio-Gate coated titanium implants have already been used in well over
a hundred single-patient revision surgeries. Single-patient cases with
antimicrobial implants are mainly performed in patients that are at risk
of infection due to previous orthopedic revisions or in cancer patients.
This is because in these patient groups, recent infections can lead to
amputations or even have life-threatening consequences.
Worldwide, patients in the EU, Switzerland, Great Britain, New Zealand,
Australia and the USA have been treated with implants coated by BioGate. In Germany, for example, implants have already been coated
for high-risk patients at the Professional University Clinic Cooperative
Murnau, University Clinic Regensburg, University Clinic Giessen.
The successful single patient revision cases have led to a strong
interest among international clinics and surgeons. By now, Bio-Gate
has accumulated an extensive amount of data from medical devices
implanted in humans and can prove the high quality of the HyProtect™
coating in practical use applications. The successful operations
together with positive scientific publications have already led to
hospitals explicitly requesting implants with Bio-Gate’s coating from
manufacturers for high-risk patients.
Thomas Konradt, Director of Business Development at Bio-Gate AG:
“We are very pleased that our cooperation partner wants to take
advantage of the new, worldwide marketing opportunities for our
HyProtect™ coating through the expanded network. The high quality
of the HyProtect™ coating, which greatly reduces the risk of reinfection in patients who are particularly at risk of infection, will thus
become even more widely known. In addition, the total number of
implants manufactured using the 3D printing process is expected to
increase in the future. This will increase the number of single patient
compassionate care cases and is extremely helpful in developing our
medical technology business into a growth driver.”
Contact: Bio-Gate AG www.bio-gate.de
THE OPERATING THEATRE JOURNAL
When responding please quote ‘OTJ’
www.otjonline.com